GRPR and neoplasm: The total number of binding sites (the sum of GRPR and integrin) for 99mTc-RGD-BBN would significantly increase as compared to the monomeric counterparts in the dual-receptor positive tumor models, which would lead to improve in vivo tumor targeting efficacy.